NCT00160277

Brief Summary

The purpose of this study is to demonstrate efficacy and safety of Moxonidine in Indian subjects.

Trial Health

80
On Track

Trial Health Score

Automated assessment based on enrollment pace, timeline, and geographic reach

Enrollment
100

participants targeted

Target at below P25 for phase_3 hypertension

Geographic Reach
1 country

3 active sites

Status
completed

Health score is calculated from publicly available data and should be used for screening purposes only.

Trial Relationships

Click on a node to explore related trials.

Study Timeline

Key milestones and dates

Study Start

First participant enrolled

July 1, 2005

Completed
2 months until next milestone

First Submitted

Initial submission to the registry

September 9, 2005

Completed
3 days until next milestone

First Posted

Study publicly available on registry

September 12, 2005

Completed
Last Updated

January 30, 2009

Status Verified

January 1, 2009

First QC Date

September 9, 2005

Last Update Submit

January 29, 2009

Conditions

Hypertension

Keywords

Efficacy and safety of moxonidine in Indian hypertensives

Outcome Measures

Primary Outcomes (1)

  • Systolic blood pressure reduction

Secondary Outcomes (1)

  • Piggy-back pharmacoeconomic evaluation; Safety and tolerability

Interventions

MoxonidineDRUG

Eligibility Criteria

Age18 Years+
Sexall
Healthy VolunteersNo
Age GroupsAdult (18-64), Older Adult (65+)

You may qualify if:

  • Hypertension

You may not qualify if:

  • Severe concomitant diseases, CHF, secondary hypertension, severe hypertension, significant hepatic disease, unstable angina

Contact the study team to confirm eligibility.

Sponsors & Collaborators

Study Sites (3)

Site 1

Jubillee Hills Hyderabad, India

Location

Site 2

Mangalore, India

Location

Site 3

New Delhi, India

Location

MeSH Terms

Conditions

Hypertension

Interventions

moxonidine

Condition Hierarchy (Ancestors)

Vascular DiseasesCardiovascular Diseases

Study Officials

  • Global Clinical Director Solvay

    Solvay Pharmaceuticals

    STUDY DIRECTOR

Study Design

Study Type
interventional
Phase
phase 3
Allocation
NON RANDOMIZED
Masking
NONE
Purpose
TREATMENT
Intervention Model
SINGLE GROUP
Sponsor Type
INDUSTRY

Study Record Dates

First Submitted

September 9, 2005

First Posted

September 12, 2005

Study Start

July 1, 2005

Last Updated

January 30, 2009

Record last verified: 2009-01

Locations

IN(3)